RxDoctor Payments Data

Jennifer de Groot

Family · Colorado Springs, CONPI 1427614882

Payments from drug & device makers

$2,050in general payments, 2019–2025

Across 42 payments — averaging $48.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$271
  • Novo Nordisk$271
  • Sanofi-aventis U.S. LLC$253
  • Amgen$207
  • Medtronic$203
  • Ascendis Pharma Endocrinology Inc$146
  • plus $698 from 9 others

What the payments were for

  • Food & beverage$2,01798%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,050 in reported general payments places this provider in the 85th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$71,813
Medicare patients
350
Services billed
4,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide122$220,864
TrulicityDulaglutide121$160,808
JardianceEmpagliflozin72$117,247
OzempicSemaglutide58$108,820
Tresiba Flextouch U-100Insulin Degludec45$58,783
Humalog Kwikpen U-200Insulin Lispro11$50,150
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$48,149
TymlosAbaloparatide14$43,344
Tresiba Flextouch U-200Insulin Degludec17$25,329
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/711$17,544
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$17,058
Humulin R U-500 KwikpenInsulin Regular, Human13$15,816
Fiasp FlextouchInsulin Aspart (Niacinamide)15$12,623
Insulin Lispro Kwikpen U-100Insulin Lispro37$12,081
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$9,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$146$392,183283 claims
Novo NordiskOzempic$271$108,82058 claims
Radius Health, Inc.Tymlos$17$43,34414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,182 family providers in Colorado.

Other family in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →